Page 1

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) The area of anti-infectives represents an exciting frontier for development of potential life-saving products. However, there are a number of issues and trends that have a direct influence on this market and manufacturers' ability to successfully operate in the market. The issues and trends affecting this market include:  Drug Resistance  HIV Trends, Cost, and Access to Drug Therapy  Other Immunocompromised Population Issues  Alliances and Partnerships  New Developments  Rx-to-OTC Switches The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives. Request a Sample for or Inquire before buying the report@ World Anti-Infectives Market Additional Information Gilead Leads Antiviral Therapy Sales: Kalorama With combined sales from the top HIV treatment on the market and several other drugs, Gilead Sciences leads the antiviral market, according to healthcare market research publisher Kalorama Information, closely followed by Bristol-Myers Squibb, Roche and Merck. Led by growth in antivirals, the market for all anti-infectives reached $53 billion in 2011, according to this new report by Kalorama Information. Atripla is the company's newest antiviral product, launched in July 2006, and it's the leading treatment for HIV. It is a nucleoside analog, part of a highly active antiretroviral therapy (HAART) regimen or "cocktail" that under best conditions can reduce the presence of HIV RNA in the patient's plasma to undetectable levels, thus prolonging survival. Kalorama estimated the product's sales to be $3.2 billion in 2011. Truvada, Viread, Hepsera are the company's other antiviral drugs. However, the report finds this is a highly competitive market and other brands are competing for market leadership. Major points covered in Table of Contents of this report include: Introduction INTRODUCTION AND INDUSTRY TRENDS ANTIFUNGAL DRUGS ANTIBACTERIAL DRUGS ANTIVIRAL DRUGS


MARKET SUMMARY CORPORATE PROFILES COMPANY DIRECTORY Explore Comprehensive list of more than Tables & Figures available in the report @ http://www.reportsnreports.com/reports/145414-world-market-for-anti-infectives-antifungalsantibacterials-and-antivirals-.html Report Details: Published: February 2012 No. of Pages: 220 Price: Single User License – US $ 3800 Contact: Priyank Tiwari 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-391-5441 sales@reportsandreports.com Visit our Market Research Blog @ http://www.reportsnreportsblog.com/ Connect With Us:

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)  

The report covers both currently marketed and late stage development products. Revenues for each segment were generated using dollar and uni...

Read more
Read more
Similar to
Popular now
Just for you